ScPharma: FDA Approves FUROSCIX For Treating Edema | World Market Information
(RTTNews) – scPharmaceuticals Inc. (SCPH) introduced that the U.S. Meals and Drug Administration (FDA) has accepted the supplemental New Drug Utility (sNDA) for FUROSCIX to increase the indication to incorporate remedy of edema in sufferers with persistent kidney illness (CKD).
SCPH closed Thursday’s common trading at $3.12 down $0.06 or 1.89%. However within the after-hours trading the stock gained $0.16 or 5.13%.
FUROSCIX (furosemide injection), 80 mg/10 mL for subcutaneous use is indicated for the remedy of edema (i.e., congestion, fluid overload, or hypervolemia) in grownup sufferers with persistent coronary heart failure or persistent kidney illness (CKD), together with the nephrotic syndrome.
FUROSCIX is predicted to be accessible for persistent kidney illness sufferers in
April 2025.
For Extra Such Well being Information, go to rttnews.com.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
Keep up to date with the latest news within the international markets! Our web site is your go-to source for cutting-edge financial news, market trends, financial insights, and updates on worldwide trade. We offer every day updates to make sure you have entry to the freshest data on stock market actions, commodity costs, currency fluctuations, and main financial bulletins.
Discover how these trends are shaping the longer term of the worldwide economic system! Go to us commonly for probably the most partaking and informative market content material by clicking right here. Our fastidiously curated articles will keep you knowledgeable on market shifts, investment methods, geopolitical impacts, and pivotal moments in international finance.
